The melanocortin family
MT-II is one member of a growing melanocortin family, and seeing it in context is the best way to understand both its a…
Where MT-II sits, and where the science went next
MT-II is one member of a growing melanocortin family, and seeing it in context is the best way to understand both its appeal and its obsolescence. This unit compares MT-II with its relatives and its real alternatives, then looks at the selective, approved drugs that represent where melanocortin science actually went.
The throughline is a hopeful one: the messy, non-selective research compound pointed the way, and the field answered with cleaner, tested, approved molecules. MT-II is best understood as a stepping stone the science has already stepped past.
Key terms
The melanocortin family side by side
MT-II is easiest to understand next to its relatives. The three Melanotan-era peptides differ in selectivity and approval status, and lining them up shows exactly what made MT-II distinctive and what made it dispensable.
The selectivity column tells a more interesting story than the usual one. Afamelanotide is genuinely MC1R-selective. PT-141 is not selective at all: the Vyleesi label describes non-selective activation with MC1R first in the order of potency, which is exactly why hyperpigmentation is a labelled warning. So there are two routes out of MT-II's problem, and only one is selectivity. The other is a capped dose and a defined indication, proven in trials. MT-II has neither, which is why it sits alone in the banned column.
AdvancedSelectivity, or a dose you are allowed to exceed
A selective drug can be studied, dosed, and approved because its effects are predictable and contained; setmelanotide and afamelanotide won that way. Bremelanotide won the other way: it is still a broad melanocortin agonist, but its trials fixed a maximum of eight doses per month, at which focal hyperpigmentation appeared in about 1% of patients rather than the 38% seen with eight consecutive daily doses. MT-II has neither a narrow target nor an enforced ceiling, so nobody can say which side of that line any given user is on.